Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 16/20 | 0.82 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | GLP1R | P43220 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7931381 | 1.00 | NOD1 (0.82) | NOD1FAAHSLC6A5GLP1R | |
| SCHEMBL7931383 | 1.00 | NOD1 (0.82) | NOD1FAAHSLC6A5GLP1R | |
| SCHEMBL7934767 | 1.00 | NOD1 (0.82) | NOD1FAAHSLC6A5GLP1R | |
| SCHEMBL7934773 | 0.92 | NOD1 (0.69) | NOD1FAAH | |
| SCHEMBL9017361 | 0.88 | NOD1 (0.64) | NOD1FAAHSLC6A5 | |
| SCHEMBL9017357 | 0.87 | NOD1 (0.62) | NOD1FAAHSLC6A5 | |
| SCHEMBL9229914 | 0.87 | NOD1 (0.62) | NOD1FAAHSLC6A5 | |
| SCHEMBL9229922 | 0.87 | NOD1 (0.62) | NOD1FAAHSLC6A5 | |
| SCHEMBL9017346 | 0.87 | NOD1 (0.62) | NOD1FAAHSLC6A5 | |
| SCHEMBL31024108 | 0.87 | NOD1 (0.78) | NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041195-A1 | COMPOSITIONS AND METHODS FOR PULMONARY SURFACTANT-BIOMIMETIC NANOPARTICLES | The General Hospital Corporation (US) | 2022-08-17 | — | — | EP | claimed |
| CN-114765953-A | Lung surfactant-biomimetic nanoparticle compositions and methods | 总医院公司 | 2022-07-19 | — | — | CN | claimed |
| EP-3796900-B1 | TRITERPENE AMINE DERIVATIVES | DFH THERAPEUTICS (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12589148-B2 | Immunity-inducing agent comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same | THE UNIVERSITY OF KITAKYUSHU (JP) | 2026-03-31 | — | — | US | disclosed |
| WO-2025224446-A1 | NOVEL CANCER ANTIGENS AND METHODS | ENARA BIO LIMITED (GB) | 2025-10-30 | — | — | WO | disclosed |
| EP-4611757-A1 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | Ramirez, Christina, M. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025133007-A1 | NOVEL CANCER ANTIGENS AND METHODS | ENARA BIO LIMITED (GB) | 2025-06-26 | — | — | WO | disclosed |
| US-20250152703-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-15 | — | — | US | disclosed |
| CN-112839674-B | Immune inducer comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same | 公立大学法人北九州市立大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-114765953-B | Compositions and methods of pulmonary surfactant-biomimetic nanoparticles | 总医院公司 | 2025-03-18 | — | — | CN | disclosed |
| US-12201684-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-21 | — | — | US | disclosed |
| US-20230144876-A1 | IMMUNE INDUCER CONTAINING POLYNUCLEOTIDE-PEPTIDE CONJUGATE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | THE UNIVERSITY OF KITAKYUSHU (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-4129344-A1 | IMMUNE INDUCER CONTAINING POLYNUCLEOTIDE-PEPTIDE CONJUGATE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | The University of Kitakyushu (JP) | 2023-02-08 | — | — | EP | disclosed |
| US-20230021483-A1 | CHARACTERISTIC ANALYSIS METHOD AND CLASSIFICATION OF PHARMACEUTICAL COMPONENTS BY USING TRANSCRIPTOMES | NAT INST BIOMEDICAL INNOVATION HEALTH & NUTRITION (JP) | 2023-01-26 | — | — | US | disclosed |
| CN-115427079-A | Immune inducer comprising polynucleotide-peptide conjugate and pharmaceutical composition comprising same | 公立大学法人北九州市立大学 | 2022-12-02 | — | — | CN | disclosed |
| US-20220362153-A1 | COMPOSITIONS AND METHODS FOR PULMONARY SURFACTANT-BIOMIMETIC NANOPARTICLES | THE GENERAL HOSPITAL CORPORATION | 2022-11-17 | — | — | US | disclosed |
| EP-4041195-A1 | COMPOSITIONS AND METHODS FOR PULMONARY SURFACTANT-BIOMIMETIC NANOPARTICLES | The General Hospital Corporation (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114765953-A | Lung surfactant-biomimetic nanoparticle compositions and methods | 总医院公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-114469958-A | Method for prophylactic treatment of viruses and pre-exposure prophylactic kit | 艾利安有限责任公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220031839-A1 | IMMUNITY-INDUCING AGENT COMPRISING ANTIGEN PEPTIDE-ADJUVANT NUCLEOTIDE CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | THE UNIVERSITY OF KITAKYUSHU (JP) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144876-A1 | IMMUNE INDUCER CONTAINING POLYNUCLEOTIDE-PEPTIDE CONJUGATE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | MICA, HLA-DRB1, CD74 | NOD1 217/4885FAAH 4830/4885SLC6A5 2901/4885 |
| US-20220031839-A1 | IMMUNITY-INDUCING AGENT COMPRISING ANTIGEN PEPTIDE-ADJUVANT NUCLEOTIDE CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TLR9, MYD88, TLR3 | NOD1 33/4885FAAH 4459/4885SLC6A5 4417/4885 |
| US-12589148-B2 | Immunity-inducing agent comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same | MYD88, TLR9, CD74 | NOD1 16/4885FAAH 4866/4885SLC6A5 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.